no BE between early phase and Phase 3 formulations [Regulatives / Guidelines]

posted by fno Homepage – Belgium, 2020-01-22 18:11 (1527 d 00:44 ago) – Posting: # 21080
Views: 2,594

Thanks Helmut for your feed-back!

❝ Without digging into guidelines: No. What we have in Phase I/II is sometimes not what I would call a ‘formulation’ in the biopharmaceutical sense at all. Anything goes: Manually filled capsules, lab-scale tablet-presses, etc.


Indeed.

❝ Doesn’t matter because we are interested in PK (I) and safety (II).


OK but then how to justify in the dossier the extrapolation of some early phase outcomes, e.g. a food effect or an efficacy and/or safety exposure signal... should these key findings be evaluated/demonstrated again with the final formulation?

❝ Once you move to phase III you are bound to cGMP (though still in pilot-scale). Only when you move from III to the to be marketed formulation, the applicable SUPAC guidance (IR, MR, SS) cut in and very likely you need a BE study.


Yep.

Thank you!

Kind regards,
Fabrice

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
97 visitors (0 registered, 97 guests [including 9 identified bots]).
Forum time: 18:55 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5